Vascular adverse events with nilotinib in chronic myeloid leulakaemia patients should ideally be managed by stopping the drug due to the high risk of recurrence, Australian experience shows. A retrospective review of adverse events with the second generation TKI in 220 patients with CML in chronic phase found that vascular adverse events occurred in 26 ...
Stop or switch the best way to manage nilotinib vascular adverse events
By Michael Woodhead
29 Apr 2019